Open1.630 | Close1.625 |
Vol / Avg.15.639K / 50.628K | Mkt Cap74.056M |
Day Range1.595 - 1.630 | 52 Wk Range1.390 - 5.560 |
Intercure Stock (NASDAQ: INCR) stock price, news, charts, stock research, profile.
Open1.630 | Close1.625 |
Vol / Avg.15.639K / 50.628K | Mkt Cap74.056M |
Day Range1.595 - 1.630 | 52 Wk Range1.390 - 5.560 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.030 | ||||||
REV | 28.090M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-04-12 | TD Cowen | Vivien Azer | Maintains | Outperform | Lowers | 10.00 | 5.00 |
2017-12-11 | Barclays | Jack Meehan | Initiates Coverage On | Equal-Weight | Announces | - | 40.00 |
2017-11-14 | Credit Suisse | Erin Wilson | Maintains | Outperform | Lowers | 68.00 | 54.00 |
2017-11-13 | Keybanc | Donald Hooker | Maintains | Overweight | Lowers | 68.00 | 46.00 |
You can purchase shares of Intercure (NASDAQ: INCR) through any online brokerage.
There are no as such competitors for Intercure.
The latest price target for Intercure (NASDAQ: INCR) was reported by TD Cowen on Wednesday, April 12, 2023. The analyst firm set a price target for 5.00 expecting INCR to rise to within 12 months (a possible 207.69% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Intercure (NASDAQ: INCR) is $1.625 last updated Today at September 22, 2023 at 7:59 PM UTC.
There is no dividend information for Intercure.
Intercure’s Q3 earnings are confirmed for Tuesday, November 14, 2023.
There is no upcoming split for Intercure.
Intercure is in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry. They are listed on the NASDAQ.
Intercure Stock (NASDAQ: INCR) stock price, news, charts, stock research, profile.
Open1.630 | Close1.625 |
Vol / Avg.15.639K / 50.628K | Mkt Cap74.056M |
Day Range1.595 - 1.630 | 52 Wk Range1.390 - 5.560 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.030 | ||||||
REV | 28.090M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-04-12 | TD Cowen | Vivien Azer | Maintains | Outperform | Lowers | 10.00 | 5.00 |
2017-12-11 | Barclays | Jack Meehan | Initiates Coverage On | Equal-Weight | Announces | - | 40.00 |
2017-11-14 | Credit Suisse | Erin Wilson | Maintains | Outperform | Lowers | 68.00 | 54.00 |
2017-11-13 | Keybanc | Donald Hooker | Maintains | Overweight | Lowers | 68.00 | 46.00 |
You can purchase shares of Intercure (NASDAQ: INCR) through any online brokerage.
There are no as such competitors for Intercure.
The latest price target for Intercure (NASDAQ: INCR) was reported by TD Cowen on Wednesday, April 12, 2023. The analyst firm set a price target for 5.00 expecting INCR to rise to within 12 months (a possible 207.69% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Intercure (NASDAQ: INCR) is $1.625 last updated Today at September 22, 2023 at 7:59 PM UTC.
There is no dividend information for Intercure.
Intercure’s Q3 earnings are confirmed for Tuesday, November 14, 2023.
There is no upcoming split for Intercure.
Intercure is in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry. They are listed on the NASDAQ.
Intercure Stock (NASDAQ: INCR) stock price, news, charts, stock research, profile.
Open1.630 | Close1.625 |
Vol / Avg.15.639K / 50.628K | Mkt Cap74.056M |
Day Range1.595 - 1.630 | 52 Wk Range1.390 - 5.560 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.030 | ||||||
REV | 28.090M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-04-12 | TD Cowen | Vivien Azer | Maintains | Outperform | Lowers | 10.00 | 5.00 |
2017-12-11 | Barclays | Jack Meehan | Initiates Coverage On | Equal-Weight | Announces | - | 40.00 |
2017-11-14 | Credit Suisse | Erin Wilson | Maintains | Outperform | Lowers | 68.00 | 54.00 |
2017-11-13 | Keybanc | Donald Hooker | Maintains | Overweight | Lowers | 68.00 | 46.00 |
You can purchase shares of Intercure (NASDAQ: INCR) through any online brokerage.
There are no as such competitors for Intercure.
The latest price target for Intercure (NASDAQ: INCR) was reported by TD Cowen on Wednesday, April 12, 2023. The analyst firm set a price target for 5.00 expecting INCR to rise to within 12 months (a possible 207.69% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Intercure (NASDAQ: INCR) is $1.625 last updated Today at September 22, 2023 at 7:59 PM UTC.
There is no dividend information for Intercure.
Intercure’s Q3 earnings are confirmed for Tuesday, November 14, 2023.
There is no upcoming split for Intercure.
Intercure is in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry. They are listed on the NASDAQ.
Intercure Stock (NASDAQ: INCR) stock price, news, charts, stock research, profile.
Open1.630 | Close1.625 |
Vol / Avg.15.639K / 50.628K | Mkt Cap74.056M |
Day Range1.595 - 1.630 | 52 Wk Range1.390 - 5.560 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.030 | ||||||
REV | 28.090M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-04-12 | TD Cowen | Vivien Azer | Maintains | Outperform | Lowers | 10.00 | 5.00 |
2017-12-11 | Barclays | Jack Meehan | Initiates Coverage On | Equal-Weight | Announces | - | 40.00 |
2017-11-14 | Credit Suisse | Erin Wilson | Maintains | Outperform | Lowers | 68.00 | 54.00 |
2017-11-13 | Keybanc | Donald Hooker | Maintains | Overweight | Lowers | 68.00 | 46.00 |
You can purchase shares of Intercure (NASDAQ: INCR) through any online brokerage.
There are no as such competitors for Intercure.
The latest price target for Intercure (NASDAQ: INCR) was reported by TD Cowen on Wednesday, April 12, 2023. The analyst firm set a price target for 5.00 expecting INCR to rise to within 12 months (a possible 207.69% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Intercure (NASDAQ: INCR) is $1.625 last updated Today at September 22, 2023 at 7:59 PM UTC.
There is no dividend information for Intercure.
Intercure’s Q3 earnings are confirmed for Tuesday, November 14, 2023.
There is no upcoming split for Intercure.
Intercure is in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry. They are listed on the NASDAQ.
Intercure Stock (NASDAQ: INCR) stock price, news, charts, stock research, profile.
Open1.630 | Close1.625 |
Vol / Avg.15.639K / 50.628K | Mkt Cap74.056M |
Day Range1.595 - 1.630 | 52 Wk Range1.390 - 5.560 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.030 | ||||||
REV | 28.090M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-04-12 | TD Cowen | Vivien Azer | Maintains | Outperform | Lowers | 10.00 | 5.00 |
2017-12-11 | Barclays | Jack Meehan | Initiates Coverage On | Equal-Weight | Announces | - | 40.00 |
2017-11-14 | Credit Suisse | Erin Wilson | Maintains | Outperform | Lowers | 68.00 | 54.00 |
2017-11-13 | Keybanc | Donald Hooker | Maintains | Overweight | Lowers | 68.00 | 46.00 |
You can purchase shares of Intercure (NASDAQ: INCR) through any online brokerage.
There are no as such competitors for Intercure.
The latest price target for Intercure (NASDAQ: INCR) was reported by TD Cowen on Wednesday, April 12, 2023. The analyst firm set a price target for 5.00 expecting INCR to rise to within 12 months (a possible 207.69% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Intercure (NASDAQ: INCR) is $1.625 last updated Today at September 22, 2023 at 7:59 PM UTC.
There is no dividend information for Intercure.
Intercure’s Q3 earnings are confirmed for Tuesday, November 14, 2023.
There is no upcoming split for Intercure.
Intercure is in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry. They are listed on the NASDAQ.
Intercure Stock (NASDAQ: INCR) stock price, news, charts, stock research, profile.
Open1.630 | Close1.625 |
Vol / Avg.15.639K / 50.628K | Mkt Cap74.056M |
Day Range1.595 - 1.630 | 52 Wk Range1.390 - 5.560 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.030 | ||||||
REV | 28.090M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-04-12 | TD Cowen | Vivien Azer | Maintains | Outperform | Lowers | 10.00 | 5.00 |
2017-12-11 | Barclays | Jack Meehan | Initiates Coverage On | Equal-Weight | Announces | - | 40.00 |
2017-11-14 | Credit Suisse | Erin Wilson | Maintains | Outperform | Lowers | 68.00 | 54.00 |
2017-11-13 | Keybanc | Donald Hooker | Maintains | Overweight | Lowers | 68.00 | 46.00 |
You can purchase shares of Intercure (NASDAQ: INCR) through any online brokerage.
There are no as such competitors for Intercure.
The latest price target for Intercure (NASDAQ: INCR) was reported by TD Cowen on Wednesday, April 12, 2023. The analyst firm set a price target for 5.00 expecting INCR to rise to within 12 months (a possible 207.69% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Intercure (NASDAQ: INCR) is $1.625 last updated Today at September 22, 2023 at 7:59 PM UTC.
There is no dividend information for Intercure.
Intercure’s Q3 earnings are confirmed for Tuesday, November 14, 2023.
There is no upcoming split for Intercure.
Intercure is in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry. They are listed on the NASDAQ.
Intercure Stock (NASDAQ: INCR) stock price, news, charts, stock research, profile.
Open1.630 | Close1.625 |
Vol / Avg.15.639K / 50.628K | Mkt Cap74.056M |
Day Range1.595 - 1.630 | 52 Wk Range1.390 - 5.560 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.030 | ||||||
REV | 28.090M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-04-12 | TD Cowen | Vivien Azer | Maintains | Outperform | Lowers | 10.00 | 5.00 |
2017-12-11 | Barclays | Jack Meehan | Initiates Coverage On | Equal-Weight | Announces | - | 40.00 |
2017-11-14 | Credit Suisse | Erin Wilson | Maintains | Outperform | Lowers | 68.00 | 54.00 |
2017-11-13 | Keybanc | Donald Hooker | Maintains | Overweight | Lowers | 68.00 | 46.00 |
You can purchase shares of Intercure (NASDAQ: INCR) through any online brokerage.
There are no as such competitors for Intercure.
The latest price target for Intercure (NASDAQ: INCR) was reported by TD Cowen on Wednesday, April 12, 2023. The analyst firm set a price target for 5.00 expecting INCR to rise to within 12 months (a possible 207.69% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Intercure (NASDAQ: INCR) is $1.625 last updated Today at September 22, 2023 at 7:59 PM UTC.
There is no dividend information for Intercure.
Intercure’s Q3 earnings are confirmed for Tuesday, November 14, 2023.
There is no upcoming split for Intercure.
Intercure is in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry. They are listed on the NASDAQ.
Intercure Stock (NASDAQ: INCR) stock price, news, charts, stock research, profile.
Open1.630 | Close1.625 |
Vol / Avg.15.639K / 50.628K | Mkt Cap74.056M |
Day Range1.595 - 1.630 | 52 Wk Range1.390 - 5.560 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.030 | ||||||
REV | 28.090M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-04-12 | TD Cowen | Vivien Azer | Maintains | Outperform | Lowers | 10.00 | 5.00 |
2017-12-11 | Barclays | Jack Meehan | Initiates Coverage On | Equal-Weight | Announces | - | 40.00 |
2017-11-14 | Credit Suisse | Erin Wilson | Maintains | Outperform | Lowers | 68.00 | 54.00 |
2017-11-13 | Keybanc | Donald Hooker | Maintains | Overweight | Lowers | 68.00 | 46.00 |
You can purchase shares of Intercure (NASDAQ: INCR) through any online brokerage.
There are no as such competitors for Intercure.
The latest price target for Intercure (NASDAQ: INCR) was reported by TD Cowen on Wednesday, April 12, 2023. The analyst firm set a price target for 5.00 expecting INCR to rise to within 12 months (a possible 207.69% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Intercure (NASDAQ: INCR) is $1.625 last updated Today at September 22, 2023 at 7:59 PM UTC.
There is no dividend information for Intercure.
Intercure’s Q3 earnings are confirmed for Tuesday, November 14, 2023.
There is no upcoming split for Intercure.
Intercure is in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry. They are listed on the NASDAQ.
Intercure Stock (NASDAQ: INCR) stock price, news, charts, stock research, profile.
Open1.630 | Close1.625 |
Vol / Avg.15.639K / 50.628K | Mkt Cap74.056M |
Day Range1.595 - 1.630 | 52 Wk Range1.390 - 5.560 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.030 | ||||||
REV | 28.090M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-04-12 | TD Cowen | Vivien Azer | Maintains | Outperform | Lowers | 10.00 | 5.00 |
2017-12-11 | Barclays | Jack Meehan | Initiates Coverage On | Equal-Weight | Announces | - | 40.00 |
2017-11-14 | Credit Suisse | Erin Wilson | Maintains | Outperform | Lowers | 68.00 | 54.00 |
2017-11-13 | Keybanc | Donald Hooker | Maintains | Overweight | Lowers | 68.00 | 46.00 |
You can purchase shares of Intercure (NASDAQ: INCR) through any online brokerage.
There are no as such competitors for Intercure.
The latest price target for Intercure (NASDAQ: INCR) was reported by TD Cowen on Wednesday, April 12, 2023. The analyst firm set a price target for 5.00 expecting INCR to rise to within 12 months (a possible 207.69% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Intercure (NASDAQ: INCR) is $1.625 last updated Today at September 22, 2023 at 7:59 PM UTC.
There is no dividend information for Intercure.
Intercure’s Q3 earnings are confirmed for Tuesday, November 14, 2023.
There is no upcoming split for Intercure.
Intercure is in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry. They are listed on the NASDAQ.